Company intelligence / Profile preview

SpikImm

Ownership: Private
Development stage: Phase 1

Overview

SPK001 has completed Phase 1 clinical trials with excellent safety and pharmacokinetics profile. The company is preparing for Phase 2 trials expected to begin in Q2 2023. SPK002 is in advanced regulatory preclinical development and expected to enter clinical trials in Q2 2023.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

4 assets

SPK002

3 more assets in the full pipeline.

Partnerships

Institut PasteurXencorSATT Conectus

Beyond the preview

Go deeper on SpikImm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpikImm.